Trial
NCT02577094
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Nantes University Hospital
Collaborators
Gilead Sciences; Institut Cancerologie de l'Ouest
Condition
Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Intervention
90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-24